High blood pressure: you’re not alone. Under the latest guidelines, about 45.4% of US adults have high blood pressure.1*

That means more Americans than ever before are living with this condition.1 EDARBI and EDARBYCLOR are powerful choices for you and your doctor to consider.2,3
*95% confidence interval of 43.9%-46.9% and 101.9-108.8 million US adults.1 Based on a comparison of adults living with hypertension in 2014 vs. 2017.1

Take Control With
a Powerful ARB

EDARBI is an ARB that may reduce your blood pressure. Clinical studies have shown Edarbi is more effective in lowering blood pressure than Benicar® (olmesartan medoxomil) or Diovan® (valsartan).1

Abbreviation: ARB = angiotension II receptor blocker

Get To Know EDARBI

Take Control With a
Powerful ARB + Diuretic

If a single medication hasn’t helped lower your blood pressure, EDARBYCLOR may be the answer. EDARBYCLOR showed statistically superior blood pressure control vs Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide) in a head-to-head study.2

Learn More About
High Blood Pressure
And What You Can Do to Take Control

Millions of people just like you are monitoring and managing their blood pressure every day. Learn about causes, risks, guidelines, and more—and find a guide to taking your own blood pressure.

Start learning now

Save on EDARBI and EDARBYCLOR, Whatever Your INSURANCE Coverage

No matter what your current insurance coverage is, we have programs that may help you get the prescription treatment you need at a cost you can afford. Even if you’re between insurance or underinsured right now, we have programs to help you get access to the prescriptions you need.
Click here to see our prescription savings programs


Click below to discover which savings program is best for you.
Find your savings program

1. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults: An Analysis of National Data. JAMA Cardiol. 2018;3(7):572-581. doi:10.1001/jamacardio.2018.1240
2. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413-420. doi:10.1161/HYPERTENSIONAHA.110.163402
3. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310-318.